Ulkavis tab n / 120mg film about 28 pc

Description

Composition
Active substance:
1 tablet contains:
Bismuth tripotassium dicitratobismuthate 303.03 mg (equivalent bismuth oxide 120,00 mg).
Excipients:
Corn starch 72.17 mg 18.00 mg Povidone K30, potassium polikrilin 23.80 mg Macrogol 6000 6.00 mg magnesium stearate 2.00 mg
Sheath: titanium dioxide (E171) 1.50 mg, 4.505 mg polyvinyl alcohol, Macrogol 4000 2.295 mg, 1.70 mg talc.
Description:
Tablets, film-coated. Round slightly biconvex tablets, film-coated white or almost white, with beveled.
View of the fracture: a rough mass of white color with a cover white or nearly white.
Product form:
Tablets, film-coated, 120 mg.
10 or 14 or 15 tablets in the blister of the composite material (OPA / Al / PVC) – aluminum foil (OPA / Al / PVC-Al).
At 2, 4, 8 and 16 of blisters (the blister 14 tablets) or 3, 4, 6, 10 and 24 of blisters (the blister 10 tablets), or 2, 4, 8 and 16 of blisters (the blister 15 tablets) together with instructions for use placed into cardboard pack.
Contraindications
Severe renal failure (less than 30 ml / min creatinine clearance), pregnancy, lactation, individual drug intolerance, children up to 4 years.
Dosage
120 mg
Indications
Gastric ulcer and duodenal ulcer in the acute phase, including those associated with Helicobacter pylori.
Chronic gastritis and gastroduodenitis in the acute phase, including those associated with Helicobacter pylori.
Syndrome irritable bowel, flowing mostly with symptoms of diarrhea.
Functional dyspepsia is not related to organic disease of the gastrointestinal tract.
Interaction with other drugs
Within half an hour before and after taking the drug Ulkavis not recommend the use of other drugs into and receiving food and liquids, in particular, antacids, milk, fruit and fruit juices. This is due to the fact that they, while ingestion may affect the efficacy of the drug Ulkavis.
The simultaneous use of the drug Ulkavis with tetracycline reduces the absorption of the latter.
Overdose
Overdosing Ulkavis drug induced prolonged intake of doses exceeding recommended may cause renal dysfunction. These symptoms are completely reversible cases Ulkavis drug.
When the symptoms of poisoning should: wash out the stomach, take activated charcoal and saline laxatives. Subsequently, treatment should be symptomatic. In the case of impaired renal function, which is accompanied by a high concentration of bismuth in the blood plasma, it is possible to assign chelators (penicillamine, dimercaprol). In the case of the expressed human kidney hemodialysis shown.
pharmachologic effect
Pharmacological group:
Intestinal antiseptic and astringent.
Pharmacodynamics:
Antiulcer agent with antibacterial activity against Helicobacter pylori. Also has anti-inflammatory and astringent. In the acidic environment of the stomach precipitated insoluble bismuth oxychloride and citrate chelated compound formed from a proteinaceous substrate a protective film on the surface of ulcers and erosions. By increasing the synthesis of prostaglandin E, mucus secretion and bicarbonate, stimulates activity of cytoprotective mechanisms increases resistance mucosa of the gastrointestinal tract to the action of pepsin, hydrochloric acid, enzymes and bile salts. Leads to the accumulation of epidermal growth factor in the defect area. Reduces the activity of pepsin.
Pharmacokinetics:
Bismuth subcitrate is practically not absorbed from the gastrointestinal tract. Derived mainly through the intestine to feces. A small amount of bismuth, arrived in the blood plasma, removed from the body by the kidneys.
Pregnancy and breast-feeding
Use of the drug Ulkavis during pregnancy and lactation is contraindicated.
Conditions of supply of pharmacies
Without a prescription.
side effects
From the digestive system: may cause nausea, vomiting, more frequent stools, constipation. These phenomena are not dangerous to health and are temporary in nature.
Allergic reactions: skin rash, pruritus.
With prolonged use at high doses may encephalopathy associated with the accumulation of bismuth in the central nervous system.
special instructions
Ulkavis The drug should not be used more than 8 weeks. It is also not recommended during treatment exceed the daily dose for adults and children. The period of treatment should not be used Ulkavis other medicinal preparations containing bismuth. Upon completion of a course of treatment at the recommended doses of active substance concentration in the blood plasma does not exceed 3-58 g / l, and the toxicity is observed only with plasma concentrations above 100 g / l.
In applying the drug may Ulkavis fecal staining in dark color due to the formation of bismuth sulphide. Sometimes there is a slight darkening of the tongue.
Data on the effect of the drug Ulkavis on ability to drive and there are no mechanisms.
Storage conditions
At temperatures above 25 C, in the original package.
Keep out of the reach of children.
Dosing and Administration
Adults and children over 12 years of drug Ulkavis appoint 1 tablet 4 times a day 30 minutes before meals and at bedtime or 2 tablets 2 times a day 30 minutes before meals.
Children from 8 to 12 years Ulkavis drug appoint 1 tablet 2 times a day for 30 minutes before eating.
To children of 4 to 8 years administered in a dose of 8 mg / kg / day, depending on the child’s body weight administered 1-2 tablets a day (or in 1-2 daily administration). Thus, the daily dose should be closest to the calculated dose (8 mg / kg / day).
Tablets are taken 30 minutes before meals with a little water.
The duration of treatment of 4-8 weeks. Over the next 8 weeks not be applied medicinal preparations containing bismuth.
For eradication of Helicobacter pylori preparation Ulkavis advisable to use in combination with other antibacterial agents having activity of H. pylori (for doctor’s recommendation).
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist